Patent US5219621A successfully refreshed from Google Patents.
US5219621A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods of treatment with diltiazem formulations
Assignee: Perrigo Pharma International DAC
•
Filing: 1992-07-22
•
Granted: 1993-06-15
•
Expires: 2012-07-22
Abstract
Abstract A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of diltiazem from the pellet at a rate allowing controlled absorption thereof over a twelve hour period following oral administration. The pellet has a dissolution rate in vitro which when measured in a dissolution apparatus (Paddle) according to U.S. Pharmacopoeia XXI in 0.05 M KCl at pH 7.0 results in not more than 35% of the total diltiazem being released after 2 hours of measurement. Not more than 80% of the total diltiazem is released after six hours of measurement and not less than 85% of the total diltiazem is released after 13 hours of measurement.
Inventors
- 👤 Edward J. Geoghegan
- 👤 Seamus Mulligan
- 👤 Donald E. Panoz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 20:54
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5073; A61K9/5078; A61K31/00; A61K31/33; A61K31/395; A61K31/55
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
142 words
A method of treating or controlling blood pressure in a subject suffering from mild to moderate hypertension comprising administering to said subject on a once per 12 hour basis a dose, effective to lower the blood pressure of said subject throughout said 12 hour period, of a diltiazem containing controlled absorption formulation comprising a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, said core surrounded by a multi-layered polymeric membrane, each layer containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming water soluble synthetic polymer, the ratio of said diltiazem to organic acid and the ratio of water insoluble polymer to water soluble polymer being effective to provide peak blood pressure lowering levels in the blood 4 to 12 hours following administration.
Claim 2
Independent Claim
142 words
A method of treating or controlling blood pressure in a subject suffering from mild to moderate hypertension comprising administering to said subject on a once per 12 hour basis a dose, effective to lower the blood pressure of said subject throughout said 12 hour period, of a diltiazem containing controlled absorption formulation comprising a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, said core surrounded by a multi-layered polymeric membrane, each layer containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming water soluble synthetic polymer, the ratio of said diltiazem to organic acid and the ratio of water insoluble polymer to water soluble polymer being effective to provide peak blood pressure lowering levels in the blood 4 to 12 hours following administration.
Claim 3
Dependent Claim
23 words
The method according to claim 1 wherein the ratio of the diltiazem component and the organic acid is from about 50:1 to 1:1.
Claim 4
Independent Claim
140 words
A method of treating or controlling blood pressure in a subject suffering from mild to moderate hypertension/comprising administering to said subject on a once per 12 hour basis a dose, effective to lower the blood pressure of said subject throughout said 12 hour period, of a diltiazem containing controlled absorption formulation comprising a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, said core surrounded by a multi-layered polymeric membrane, each layer containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming water soluble synthetic polymer, the ratio of said diltiazem to organic acid and the ratio of water insoluble polymer to water soluble polymer being effective to provide peak myocardium oxygenating levels in the blood 4 to 12 hours following administration.
Claim 5
Independent Claim
140 words
A method of treating or controlling blood pressure in a subject suffering from mild to moderate hypertension/comprising administering to said subject on a once per 12 hour basis a dose, effective to lower the blood pressure of said subject throughout said 12 hour period, of a diltiazem containing controlled absorption formulation comprising a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, said core surrounded by a multi-layered polymeric membrane, each layer containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming water soluble synthetic polymer, the ratio of said diltiazem to organic acid and the ratio of water insoluble polymer to water soluble polymer being effective to provide peak myocardium oxygenating levels in the blood 4 to 12 hours following administration.
Claim 6
Dependent Claim
22 words
The method of claim 3 wherein the ratio of the diltiazem component and the organic acid is from about 50:1 to 1:1.
References Cited (Backward Citations)
US2853420A
Cited
US4459279A
Cited
US4443497A
Cited
US4496558A
Cited
US4747845A
Cited
US4721619A
Cited
US4681755A
Cited
US4786500A
Cited
US4792452A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-06-14 | 1996-12-14 | 1997-06-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-06-14 | 2000-12-14 | 2001-06-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-06-14 | 2004-12-14 | 2005-06-15 | $7700.00 | Window Closed / Lapsed |